Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Alpha Cognition Inc. (ACOGF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.4910+0.0060 (+1.24%)
At close: 12:52PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • O
    Oscar
    The prospect with the company seems reasonable. However near term benefit seems elusive. My best guess it’s a bear trap for at least a year maybe a little more. I’ll revisit ina few months to see if anything has changed. Good luck guys and gals. TGIF!
  • b
    bud
    Tommy , I Also Was Surprise About , Alpha Cognition , Announce's Positive Result's In Their Alzheimer's Disease , From Pivotal Study , With , ALPHA - 1062 , In Vancouver , British Columbia , The Announcement Came In On , June 22nd. , 2022 , This Stock Should Be , Around $3.50 ; This Is Great New's , ( ACOGF ) , We Will Keep Buying More Share's Every Week ; G . L . . Tommy ,
    Bullish
  • S
    Saved by grace
    Trusting in JESUS
  • Y
    Yarg the Destroyer
    Something is going on with this company... Not sure what yet, but perhaps a merger is my guess.
  • B
    Burrill
    I would rather put my money in SAVA. Do your own due diligence.
  • D
    David
    Nothong matters except what the market makers want to do. Read their minds and you win lol
  • B
    Brent
    So a less symptomatic version of an existing drug? No wonder you're sitting under a dollar.
  • J
    John
    Canadian rx Company - baaaaaa
  • R
    Rudolph
    Prodrug data anytime now.
  • R
    Rudolph
    Still waiting on that data read…
    Bullish
  • R
    Rudolph
    So was that. Yahoo glitch or did someone put in a market order?
  • N
    Nan
    $ACOG.v just published the updated version of their corporate presentation which includes latest information on all their projects. https://www.alphacognition.com/_resources/presentations/corporate-presentation.pdf?v=0.6
    I suggest you check it out, it contains quite a few updates and new information like the latest in ALPHA-1062 - a patented, proposed treatment for mild-to-moderate Alzheimer’s Dementia and TBI’s (Traumatic Brain Injury). A lot of interesting stuff in there + investor considerations. Good to read

    td, $ACOG.v trading at $1.10 with market cap at $67.65 M
  • R
    Rudolph
    Been looking around here and there and there is not much chatter at all about this company! Talk about flying under the radar. Huge potential as younger investors like to make discoveries and share them.
    Bullish
  • p
    partystocker
    Alpha Cognition is continuing to look like a strong buy in the pre-revenue biopharma market.

    $ACOG’s ALPHA-1062 belongs to a class of drugs that are currently the standard form of care for Alzheimer's. The benefit of ALPHA-1062 is that it offers effective treatment without the majority of gastrointestinal side effects brought on by other drugs in the same class. 45% of patients who discontinue the use of these acetylcholinesterase inhibitor drugs (AChEI), do so for these reasons.

    With the AChEI market being around $5 billion, capturing even a small percent of this market represents a massive opportunity for $ACOG, currently valued at $63.96 million.

    $ACOG.V has strong data on ALPHA-1062 with a low bar for approval where it requires only bioequivalence rather than efficacy. This makes its Phase 3 trial faster and smaller than typical, with a New Drug Application planned for 2022.

    With some analysts speculating a $5 price target for $ACOG, that puts potential earnings at this point around 382%.

    $ACOG is currently trading at $1.04 and is valued at an MCAP of $63.96 million.

    https://www.cantechletter.com/2021/12/three-canadian-biopharma-stocks-for-2022/#
    To help navigate any rough waters over the year ahead, Cantech Letter has three names in the biopharma space with recent positive reviews by analysts, delivered here in no particular order.
    To help navigate any rough waters over the year ahead, Cantech Letter has three names in the biopharma space with recent positive reviews by analysts, delivered here in no particular order.
    www.cantechletter.com
  • S
    StockHawk
    As boomers begin to enter old age more and more of the population will be elderly. This fundamental change in the makeup of our population should be kept in mind when making long-term investments and is one of the reasons why Alpha Cognition ( $ACOG.V $ACOGF ) is one of my picks.

    Almost 6% of people 75-80 and diagnosed with dementia (including Alzheimer's) that number jumps up to about 12% from 80-85 and almost a quarter of people 85+ are affected.There already is a huge demand for dementia and Alzheimer's treatment and that demand will only be growing as boomers age. (source: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/dementia-highlights-canadian-chronic-disease-surveillance.html)

    $ACOG is a biopharmaceutical company that is developing new medication for neurodegenerative disorders like Alzheimer's and ALS.

    Today the company announced that their ALPHA-1062 drug (which has been shown to help with the effects of Alzheimer's) was found to help with traumatic brain injury, reducing the extent of functional deficits, and improved functional recovery of animals with brain injuries.

    In most functional measures of recovery, the animals treated with ALPHA-1062 were statistically indistinguishable from uninjured animals.

    This study really displays the power of their ALPHA-1062 drug, and these results are great for stakeholders to hear.

    $ACOG at just $0.98, MC $62.11M

    https://finance.yahoo.com/news/alpha-cognition-announce-data-pre-140000753.html
    Dementia in Canada, including Alzheimer's Disease: Highlights from the Canadian Chronic Disease Surveillance System
    Dementia in Canada, including Alzheimer's Disease: Highlights from the Canadian Chronic Disease Surveillance System
    www.canada.ca
  • S
    StockHawk
    Amazing news for anyone invested in Alpha Cognition ( $ACOG.V $ACOGF ) or anyone affected by Alzheimer's disease.

    Last week $ACOG announced that they will begin clinical trials of its drug used to treat symptoms of Alzheimer’s disease

    In Q3 this year, the $ACOG will initiate its pivotal trial to treat the symptoms associated with Alzheimer’s.

    $ACOG's lead drug, ALPHA-1062, is targeted for release in the beginning of 2022. This will put it on track for approval in 2023.

    $ACOG is selling at only $1.32 (down 2.2% today) which considering how they are on track to release a drug for a disease that is so widespread and hard to treat, I think is very undervalued

    https://www.youtube.com/watch?v=4S4g1dVckN8&feature=emb_title
    Alpha Cognition to begin its pivotal clinical trial to treat symptoms of Alzheimer’s disease
    www.youtube.com
  • N
    Nan
    if you missed the virtual webcast by $ACOG.v that aired in December, you can watch it here: https://www.youtube.com/watch?v=7yedTIaVGec
    The video includes in-dept analysis of ongoing projects and trials and other updates on the company. highly recommend watching.

    td, $ACOG.v trading at $1,08 with market cap at $66.42 M
    Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) Webcast (December 2021) | SNN Network
    www.youtube.com
  • M
    Micheal
    "Crystal Bridge Enters into Arrangement Agreement with Alpha Cognition, Announces up to $13 Million Private Placement | MarketScreener" https://www.marketscreener.com/amp/quote/stock/ALPHACOGNITION-INC-49479447/news/Crystal-Bridge-Enters-into-Arrangement-Agreement-with-Alpha-Cognition-Announces-up-to-13-Million-P-31629581/
  • R
    Rudolph
    Strong moves into a long weekend!
    Bullish
Advertisement
Advertisement